S&P 500   4,366.62 (-1.72%)
DOW   34,387.97 (-1.38%)
QQQ   361.97 (-2.26%)
AAPL   142.75 (-1.80%)
MSFT   285.78 (-2.85%)
FB   342.87 (-3.03%)
GOOGL   2,739.25 (-2.91%)
TSLA   782.63 (-1.10%)
AMZN   3,326.96 (-2.31%)
NVDA   209.13 (-3.45%)
BABA   152.97 (+1.86%)
NIO   35.31 (-3.97%)
CGC   14.30 (-2.79%)
GE   106.61 (+1.20%)
MU   74.06 (-1.49%)
AMD   102.63 (-5.11%)
T   27.33 (-0.26%)
F   14.42 (+1.84%)
ACB   6.83 (+6.89%)
DIS   175.46 (-1.57%)
PFE   43.24 (-0.76%)
BA   220.26 (-1.74%)
AMC   37.96 (-3.41%)
S&P 500   4,366.62 (-1.72%)
DOW   34,387.97 (-1.38%)
QQQ   361.97 (-2.26%)
AAPL   142.75 (-1.80%)
MSFT   285.78 (-2.85%)
FB   342.87 (-3.03%)
GOOGL   2,739.25 (-2.91%)
TSLA   782.63 (-1.10%)
AMZN   3,326.96 (-2.31%)
NVDA   209.13 (-3.45%)
BABA   152.97 (+1.86%)
NIO   35.31 (-3.97%)
CGC   14.30 (-2.79%)
GE   106.61 (+1.20%)
MU   74.06 (-1.49%)
AMD   102.63 (-5.11%)
T   27.33 (-0.26%)
F   14.42 (+1.84%)
ACB   6.83 (+6.89%)
DIS   175.46 (-1.57%)
PFE   43.24 (-0.76%)
BA   220.26 (-1.74%)
AMC   37.96 (-3.41%)
S&P 500   4,366.62 (-1.72%)
DOW   34,387.97 (-1.38%)
QQQ   361.97 (-2.26%)
AAPL   142.75 (-1.80%)
MSFT   285.78 (-2.85%)
FB   342.87 (-3.03%)
GOOGL   2,739.25 (-2.91%)
TSLA   782.63 (-1.10%)
AMZN   3,326.96 (-2.31%)
NVDA   209.13 (-3.45%)
BABA   152.97 (+1.86%)
NIO   35.31 (-3.97%)
CGC   14.30 (-2.79%)
GE   106.61 (+1.20%)
MU   74.06 (-1.49%)
AMD   102.63 (-5.11%)
T   27.33 (-0.26%)
F   14.42 (+1.84%)
ACB   6.83 (+6.89%)
DIS   175.46 (-1.57%)
PFE   43.24 (-0.76%)
BA   220.26 (-1.74%)
AMC   37.96 (-3.41%)
S&P 500   4,366.62 (-1.72%)
DOW   34,387.97 (-1.38%)
QQQ   361.97 (-2.26%)
AAPL   142.75 (-1.80%)
MSFT   285.78 (-2.85%)
FB   342.87 (-3.03%)
GOOGL   2,739.25 (-2.91%)
TSLA   782.63 (-1.10%)
AMZN   3,326.96 (-2.31%)
NVDA   209.13 (-3.45%)
BABA   152.97 (+1.86%)
NIO   35.31 (-3.97%)
CGC   14.30 (-2.79%)
GE   106.61 (+1.20%)
MU   74.06 (-1.49%)
AMD   102.63 (-5.11%)
T   27.33 (-0.26%)
F   14.42 (+1.84%)
ACB   6.83 (+6.89%)
DIS   175.46 (-1.57%)
PFE   43.24 (-0.76%)
BA   220.26 (-1.74%)
AMC   37.96 (-3.41%)
NASDAQ:CYRX

Cryoport Stock Forecast, Price & News

$66.75
-3.32 (-4.74 %)
(As of 09/28/2021 03:17 PM ET)
Add
Compare
Today's Range
$65.54
$71.22
50-Day Range
$55.13
$70.07
52-Week Range
$39.10
$84.97
Volume9,868 shs
Average Volume424,348 shs
Market Capitalization$3.07 billion
P/E RatioN/A
Dividend YieldN/A
Beta0.89
30 days | 90 days | 365 days | Advanced Chart
Receive CYRX News and Ratings via Email

Sign-up to receive the latest news and ratings for Cryoport and its competitors with MarketBeat's FREE daily newsletter.


Cryoport logo

About Cryoport

CryoPort, Inc. engages in the provision of logistics solutions to the life science industry. It also provides logistics solutions for biologic materials such as immunotherapies, stem cells, CAR-T cells, and reproductive cells for clients worldwide, including points-of-care, clinical research organizations central laboratories, biopharmaceuticals, contract manufacturing, health centers, and university researchers. It offers personalized medicine, immunotherapies, cellular therapies, CAR T-cell therapies, stem cell therapies, vaccines, diagnostic materials, semen, eggs, embryos, cord blood, bio-pharmaceuticals, infectious substances, and other commodities that require continuous exposure to certain ranges of precision-controlled temperatures. The company was founded on May 25, 1990 and is headquartered in Brentwood, TN.

Headlines

See More Headlines

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:CYRX
Employees
610
Year Founded
N/A

Sales & Book Value

Annual Sales
$78.70 million
Cash Flow
$0.51 per share
Book Value
$9.54 per share

Profitability

Net Income
$-32,690,000.00

Debt

Price-To-Earnings

Miscellaneous

Market Cap
$3.07 billion
Next Earnings Date
11/4/2021 (Estimated)
Optionable
Optionable

MarketRank

Overall MarketRank

2.22 out of 5 stars

Transportation Sector

54th out of 172 stocks

Pharmaceutical Preparations Industry

149th out of 666 stocks

Analyst Opinion: 2.5Community Rank: 4.7Dividend Strength: 0.0Insider Behavior: 3.3Valuation: 0.6 5 -4 -3 -2 -1 -












Cryoport (NASDAQ:CYRX) Frequently Asked Questions

Is Cryoport a buy right now?

7 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Cryoport in the last year. There are currently 7 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Cryoport stock.
View analyst ratings for Cryoport
or view top-rated stocks.

What stocks does MarketBeat like better than Cryoport?

Wall Street analysts have given Cryoport a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Cryoport wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Cryoport's next earnings date?

Cryoport is scheduled to release its next quarterly earnings announcement on Thursday, November 4th 2021.
View our earnings forecast for Cryoport
.

How were Cryoport's earnings last quarter?

Cryoport, Inc. (NASDAQ:CYRX) released its quarterly earnings data on Thursday, August, 5th. The consumer goods maker reported ($0.16) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.13) by $0.03. The consumer goods maker had revenue of $56.19 million for the quarter, compared to the consensus estimate of $51.23 million. Cryoport had a positive trailing twelve-month return on equity of 2.35% and a negative net margin of 18.85%.
View Cryoport's earnings history
.

How has Cryoport's stock been impacted by COVID-19?

Cryoport's stock was trading at $16.62 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, CYRX stock has increased by 301.7% and is now trading at $66.77.
View which stocks have been most impacted by COVID-19
.

What price target have analysts set for CYRX?

7 Wall Street analysts have issued 12-month target prices for Cryoport's shares. Their forecasts range from $75.00 to $84.00. On average, they anticipate Cryoport's share price to reach $78.86 in the next twelve months. This suggests a possible upside of 18.1% from the stock's current price.
View analysts' price targets for Cryoport
or view top-rated stocks among Wall Street analysts.

Who are Cryoport's key executives?

Cryoport's management team includes the following people:

What other stocks do shareholders of Cryoport own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Cryoport investors own include Gilead Sciences (GILD), Advanced Micro Devices (AMD), Micron Technology (MU), NVIDIA (NVDA), Taiwan Semiconductor Manufacturing (TSM), Amarin (AMRN), QUALCOMM (QCOM), Enterprise Products Partners (EPD), Pfizer (PFE) and Square (SQ).

What is Cryoport's stock symbol?

Cryoport trades on the NASDAQ under the ticker symbol "CYRX."

Who are Cryoport's major shareholders?

Cryoport's stock is owned by a variety of retail and institutional investors. Top institutional investors include BlackRock Inc. (6.53%), Invesco Ltd. (5.58%), Vanguard Group Inc. (4.98%), Blackstone Inc (2.80%), Granite Investment Partners LLC (2.49%) and Macquarie Group Ltd. (2.31%). Company insiders that own Cryoport stock include Daniel M Hancock, Daniel M Hancock, Edward J Zecchini, Freeze Parent LP Blackstone, Jerrell Shelton, Mark W Sawicki, Michael R Egeck, Richard J Berman and Robert Stefanovich.
View institutional ownership trends for Cryoport
.

Which major investors are selling Cryoport stock?

CYRX stock was sold by a variety of institutional investors in the last quarter, including Blackstone Inc, BlackRock Inc., Millennium Management LLC, Massachusetts Financial Services Co. MA, Federated Hermes Inc., Victory Capital Management Inc., Susquehanna International Group LLP, and Citadel Advisors LLC. Company insiders that have sold Cryoport company stock in the last year include Daniel M Hancock, Edward J Zecchini, Freeze Parent LP Blackstone, Mark W Sawicki, Michael R Egeck, Richard J Berman, and Robert Stefanovich.
View insider buying and selling activity for Cryoport
or view top insider-selling stocks.

Which major investors are buying Cryoport stock?

CYRX stock was bought by a variety of institutional investors in the last quarter, including Macquarie Group Ltd., Impax Asset Management Group plc, Clearbridge Investments LLC, Caas Capital Management LP, Morgan Stanley, Morgan Stanley, State Street Corp, and Bridgewater Associates LP.
View insider buying and selling activity for Cryoport
or or view top insider-buying stocks.

How do I buy shares of Cryoport?

Shares of CYRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Cryoport's stock price today?

One share of CYRX stock can currently be purchased for approximately $66.77.

How much money does Cryoport make?

Cryoport has a market capitalization of $3.07 billion and generates $78.70 million in revenue each year. The consumer goods maker earns $-32,690,000.00 in net income (profit) each year or ($0.84) on an earnings per share basis.

How many employees does Cryoport have?

Cryoport employs 610 workers across the globe.

What is Cryoport's official website?

The official website for Cryoport is www.cryoport.com.

Where are Cryoport's headquarters?

How can I contact Cryoport?

Cryoport's mailing address is 112 Westwood Place Suite 350, Brentwood TN, 37027. The consumer goods maker can be reached via phone at (949) 470-2300 or via email at [email protected].


This page was last updated on 9/28/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.